---------
If so, you may have a possible legal case against the manufacturer of the potentially dangerous drug or medical product. Simply fill out the short form below and an experienced legal expert will contact you as soon as possible!
Added October 4th, 2006
According to the manufacturer of the controversial cox-2 inhibitor Celebrex, the drug is still enjoying impressive sales and making huge profits, despite the fire it has come under over the last couple of years in relation to the serious side effects associated with it. Although the drug is still on the market, it now comes with one of the Food and Drug Administrations strongest warnings in relation to its side effects, known as a black box warning.
Pfizer has stated that the drug is still enjoying excellent sales, and has enjoyed global sales of over $470 million in the second quarter of this year, with a growth of around seventeen percent on the same period in 2005.
Officials from Pfizer, the pharmaceutical giant that manufactures Celebrex, recently spoke out to shareholders and stated: "We continue to expect full-year Celebrex revenues of at least $2 billion, an ambitious target given the ongoing pressures in the arthritis market."
It has also been noted that the drug manufacturer has started to step up its direct to consumer advertising campaigns in relation to Celebrex, despite the fact that it agreed not to run ads last year in line with requests from the FDA. Company officials state that they are now advertising the drug "in alignment with our new Direct-to-Consumer advertising principles, highlighting Celebrex's unique clinical profile and benefits."